secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K/A
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001104659-25-124226
Event type: m_and_a
Sentiment:  negative
Materiality: 0.65
Item codes: 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode files ABCJ financials; acquired co's accumulated deficit $193M, DEFJ holds 90.8% voting power
--------------------------------------------------------------------------------

- ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.
- Key asset is phase 3-ready seviprotimut-L for melanoma; intangible asset valued at $14M.
- Post-acquisition, DEFJ holds ~90.8% voting power on fully diluted basis, raising controlled-company concerns.
- Acquisition carries a repurchase option for DEFJ, potentially requiring cash settlement and disrupting operations.
- Pro forma combined financial statements for Sep 30, 2025 and Dec 31, 2024 filed as Exhibit 99.3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925124226/0001104659-25-124226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925124226/tm2533321d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-124226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer